Research programme: cancer immunotherapeutics - Lokon Pharma

Drug Profile

Research programme: cancer immunotherapeutics - Lokon Pharma

Alternative Names: LOAd 700; LOAd 713; LoCAR 1; LoCAR 2

Latest Information Update: 17 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lokon Pharma
  • Class CAR-T cell therapies; Gene therapies; Oncolytic viruses
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 16 Jun 2016 Preclinical trials in Cancer in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top